10058-F4: Precision c-Myc-Max Inhibition and TERT Pathway...

2025-11-07

10058-F4: Precision c-Myc-Max Inhibition and TERT Pathways in Stem Cell and Cancer Research

Introduction

The oncogenic transcription factor c-Myc is central to cell proliferation, metabolism, and survival. Aberrant c-Myc activity drives malignancy in numerous cancer types, making it a prime target for therapeutic intervention. 10058-F4 (SKU: A1169) is a novel, small-molecule, cell-permeable c-Myc-Max dimerization inhibitor that has redefined the toolkit available for apoptosis assays and cancer biology studies. Here, we provide an in-depth analysis of 10058-F4's mechanism, its applications in dissecting the c-Myc/Max heterodimer disruption pathway, and its unique intersection with TERT regulation and DNA repair in stem cell and cancer research.

Mechanism of Action: Disrupting the c-Myc-Max Heterodimer

The c-Myc/Max Axis and Its Role in Transcriptional Regulation

c-Myc exerts its transcriptional programs through dimerization with Max, enabling binding to E-box sequences on DNA and activation of growth-promoting genes. Disrupting this dimerization impairs c-Myc’s oncogenic potential. 10058-F4 is distinguished by its specificity: it binds to c-Myc, blocking the c-Myc/Max interface, thereby inhibiting heterodimer formation. This prevents DNA binding and suppresses c-Myc-driven transcriptional targets.

Downstream Effects: Cell Cycle Arrest and Mitochondrial Apoptosis

Upon treatment with 10058-F4, cells exhibit decreased c-Myc mRNA and protein levels. This downregulation culminates in cell cycle arrest and the induction of apoptosis via the mitochondrial pathway. Mechanistically, 10058-F4 modulates Bcl-2 family proteins and promotes cytochrome C release, activating caspase-dependent cell death. In acute myeloid leukemia (AML) cell lines (HL-60, U937, NB-4), 10058-F4 induces apoptosis in a dose- and time-dependent manner—significant effects are observed at 100 μM after 72 hours, providing a robust model for apoptosis assay development.

Pharmacological Profile and Handling

Chemically, 10058-F4 is (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one, with a molecular weight of 249.35. It is soluble in DMSO (≥24.9 mg/mL) and ethanol (≥2.64 mg/mL), but insoluble in water. For optimal use, it is supplied as a solid and should be stored at -20°C, with solutions prepared fresh to maintain activity.

Comparative Analysis: 10058-F4 Versus Alternative Approaches

While several strategies target c-Myc, including RNA interference and indirect pathway inhibitors, 10058-F4’s direct disruption of the c-Myc-Max dimer provides unparalleled specificity. RNAi approaches often suffer from incomplete knockdown and off-target effects, while indirect inhibitors risk compensatory pathway activation. In contrast, 10058-F4’s small-molecule design ensures cell permeability, rapid action, and reversibility, making it superior for mechanistic dissection and high-throughput screening in apoptosis research.

Existing articles, such as "10058-F4: Novel Insights into c-Myc Inhibition and Mitoch...", provide foundational coverage of 10058-F4’s role in apoptosis and mitochondrial pathways. Here, we extend the discussion by focusing on how 10058-F4 can serve as a bridge to stem cell-specific telomerase regulation and DNA repair, offering a new translational perspective.

Advanced Applications: From Acute Myeloid Leukemia to Prostate Cancer Xenografts

Acute Myeloid Leukemia (AML) Research

AML is characterized by uncontrolled proliferation of myeloid precursors, often driven by c-Myc overexpression. In vitro, 10058-F4 induces apoptosis in AML cell lines, establishing its value for dissecting the mitochondrial apoptosis pathway and evaluating novel combination regimens. Its dose-dependent effects enable precise modulation of c-Myc activity, facilitating studies on resistance mechanisms and synthetic lethality.

Prostate Cancer Xenograft Models

In vivo validation is critical for translational research. In SCID mice bearing human prostate cancer xenografts (DU145, PC-3), intravenous administration of 10058-F4 resulted in tumor growth inhibition, albeit with variable efficacy. This highlights the importance of tumor context and pharmacokinetics, and positions 10058-F4 as a benchmark tool for preclinical assessment of c-Myc-Max dimerization inhibitors. For researchers seeking detailed workflow guidance in these models, "10058-F4: Small-Molecule c-Myc Inhibitor for Apoptosis As..." offers practical insights, while our article delves deeper into the mechanistic and stem cell aspects.

Novel Insights: Linking c-Myc Inhibition to TERT Regulation and DNA Repair in Stem Cells

c-Myc and TERT Expression: A Nexus for Stem Cell Integrity

While c-Myc’s role in cancer is well-established, its influence over telomerase reverse transcriptase (TERT) expression in stem cells adds a new dimension to its biological significance. TERT is essential for telomere maintenance, stem cell self-renewal, and organismal longevity. Aberrant TERT expression underlies both oncogenesis and degenerative disease.

APEX2/APE2: DNA Repair, TERT Regulation, and Emerging Therapeutic Targets

A seminal study (Stern et al., 2024) demonstrated that the DNA repair enzyme APEX2 is indispensable for efficient TERT gene expression in human embryonic stem cells and melanoma, but not APEX1. APEX2 knockdown diminishes telomerase activity, and affected genes are enriched for mammalian-wide interspersed repeats (MIRs), particularly within TERT intron 2. This suggests that DNA repair at repetitive elements is a critical determinant of TERT transcription, adding a layer of regulation previously unappreciated. While existing reviews (e.g., "10058-F4: Unraveling c-Myc/Max Disruption in Cancer and T...") discuss these pathways, our focus is to synthesize the c-Myc-Max inhibition mechanism with emerging DNA repair-centric models of TERT regulation in stem cells and cancer.

Potential Synergies and Experimental Paradigms

Given that c-Myc directly regulates TERT transcription and that APEX2-dependent DNA repair modulates TERT expression, 10058-F4 provides a unique opportunity to dissect how oncogenic transcriptional programs and genome maintenance converge in stem cell and cancer models. By combining 10058-F4 with APEX2 perturbation, researchers can unravel the crosstalk between transcription factor inhibition, DNA repair, and telomerase activity, potentially identifying novel therapeutic vulnerabilities.

Practical Considerations and Experimental Design

Compound Handling and Storage

For reproducible results, 10058-F4 should be dissolved in DMSO or ethanol immediately before use. Solutions are not ideal for long-term storage due to potential degradation—aliquots of the solid compound, stored at -20°C, preserve activity for extended periods.

Expanding the Frontier: Integrative Approaches and Future Directions

The convergence of c-Myc-Max dimerization inhibition, TERT regulation, and DNA repair presents new frontiers for therapeutic discovery. By leveraging 10058-F4 in tandem with emerging genetic and epigenetic tools, researchers can systematically dissect the cellular networks sustaining stem cell pluripotency and tumorigenesis.

Notably, while other articles such as "10058-F4: Small-Molecule c-Myc Inhibitor for Advanced Apo..." emphasize translational applications in cancer models, this article uniquely integrates stem cell biology, TERT regulation, and DNA repair, proposing experimental intersections not previously explored.

Conclusion and Future Outlook

10058-F4 stands as a versatile, precision tool for interrogating c-Myc-driven transcription, apoptosis, and the emerging interface with telomerase regulation and DNA repair in both cancer and stem cell contexts. Its application goes beyond conventional apoptosis research, empowering investigators to address questions at the nexus of oncogenic signaling, genome maintenance, and cellular immortality. As the field advances, integrative studies leveraging 10058-F4 will be pivotal in unraveling the molecular logic of cancer and stem cell biology, and in identifying new therapeutic strategies.